Skip to main content

Table 1 Baseline characteristics of study cohort by use of low-dose aspirin before and after propensity score matching

From: Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study

Characteristic * Initial cohort Propensity score matched cohort
Aspirin non-user Low-dose aspirin user d † Aspirin non-user Low-dose aspirin user d †
(N = 244,882) (N = 16,183) (N = 15,849) (N = 15,849)
N (%) N (%) N (%) N (%)
Gender Male 144,933 (59.2) 9,192 (56.8) 0.0483 8,877 (56.0) 8,986 (56.7) 0.0139
Female 99,949 (40.8) 6,991 (43.2)   6,972 (44.0) 6,863 (43.3)  
Age 40-49 73,569 (30.0) 3,806 (23.5) 0.3481 3,631 (22.9) 3,737 (23.6) 0.0158
50-59 76,267 (31.1) 5,165 (31.9) 0.0356 4,690 (29.6) 5,067 (32.0) 0.0516
60-69 57,709 (23.6) 4,433 (27.4) 0.1971 4,489 (28.3 4,342 (27.4) 0.0207
70-99 37,337 (15.2) 2,779 (17.2) 0.1385 3,039 (19.2) 2,703 (17.1) 0.0551
Insurance type Health insurance 225,785 (92.2) 14,896 (92.0) 0.0212 14,032 (88.5) 14,615 (92.2) 0.1250
Medicaid 15,399 (6.3) 947 (5.9) 0.0779 1,334 (8.4) 920 (5.8) 0.1018
Switching 3,698 (1.5) 340 (2.1) 0.3086 483 (3.0) 314 (2.0) 0.0681
Type of diabetes Type 1 only 10,505 (4.3) 910 (5.6) 0.0615 1,011 (6.4) 809 (5.1) 0.0548
  Type 2 and others 234,377 (95.7) 15,273 (94.4)   14,838 (93.6) 15,040 (94.9)  
Antidiabetic medication OHA 206,194 (84.2) 14,315 (88.5) 0.1241 13,078 (82.5) 14,101 (89.0) 0.1854
OHA + insulin 38,688 (15.8) 1,868 (11.5)   2,771 (17.5) 1,748 (11.0)  
Diagnosis of essential hypertension Yes 56,688 (23.1) 7,912 (48.9) 0.5566 8,379 (52.9) 7,624 (48.1) 0.0954
Diagnosis of dyslipidemia Yes 27,592 (11.3) 4,253 (26.3) 0.3918 4,601 (29.0) 4,072 (25.7) 0.0749
Medication use Statins 28,601 (11.7) 4,283 (26.5) 0.3832 4,291 (27.1) 4,076 (25.7) 0.0308
  ACEI 11,878 (4.9) 2,266 (13.8) 0.3102 2,194 (13.8) 2,028 (12.8) 0.0308
  ARB 24,597 (10.0) 4,321 (26.7) 0.4404 4,301 (27.1) 4,063 (25.6) 0.0341
  CCB 47,268 (19.3) 6,311 (39.0) 0.4439 6,552 (41.3 6,099 (38.5) 0.0584
  Beta blockers 26,413 (10.8) 2,696 (16.7) 0.1713 3,291 (20.8) 2,624 (16.6) 0.1082
  Thiazide diuretics 30,824 (12.6) 4,481 (27.7) 0.3834 4,811 (30.4) 4,264 (26.9) 0.0764
  NSAID 145,733 (59.5) 10,155 (62.8) 0.0665 10,416 (65.7) 9,939 (62.7) 0.0628
  1. d: standardized difference.
  2. ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; NSAID: non-steroidal anti-inflammatory drugs; OHA: oral hypoglycemic agents SD: standard deviation.
  3. *Baseline characteristics for study subjects were identified within one year before index date.
  4. †Standardized difference (d) of greater than 0.1 represents meaningful imbalance between study groups.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us